NO963785D0 - Process for the treatment of 5HT2B receptor-related conditions - Google Patents
Process for the treatment of 5HT2B receptor-related conditionsInfo
- Publication number
- NO963785D0 NO963785D0 NO963785A NO963785A NO963785D0 NO 963785 D0 NO963785 D0 NO 963785D0 NO 963785 A NO963785 A NO 963785A NO 963785 A NO963785 A NO 963785A NO 963785 D0 NO963785 D0 NO 963785D0
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- related conditions
- 5ht2b receptor
- 5ht2b
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21262294A | 1994-03-11 | 1994-03-11 | |
US08/380,566 US5688807A (en) | 1994-03-11 | 1995-02-06 | Method for treating 5HT2B receptor related conditions |
US08/380,565 US5663178A (en) | 1995-02-06 | 1995-02-06 | Tetrahydro-beta carbolines |
PCT/US1995/003099 WO1995024200A1 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht2b receptor related conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963785D0 true NO963785D0 (en) | 1996-09-10 |
NO963785L NO963785L (en) | 1996-11-01 |
Family
ID=27395770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963785A NO963785L (en) | 1994-03-11 | 1996-09-10 | Process for the treatment of 5HT2B receptor-related conditions |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0749313A4 (en) |
JP (1) | JPH09510216A (en) |
CN (1) | CN1148340A (en) |
AU (1) | AU679635B2 (en) |
CA (1) | CA2185236A1 (en) |
CZ (1) | CZ264996A3 (en) |
FI (1) | FI963571A (en) |
HU (1) | HUT75522A (en) |
IL (1) | IL112958A0 (en) |
NO (1) | NO963785L (en) |
WO (1) | WO1995024200A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
JPH11503757A (en) * | 1995-04-18 | 1999-03-30 | イーライ・リリー・アンド・カンパニー | Use of ergoline compounds that produce physiological and pathological functions at 5-HT (7) receptors |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
CN1218368A (en) * | 1996-03-15 | 1999-06-02 | 伊莱利利公司 | Method for treating common cold or allergic rhinitis |
US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
DE69729211T2 (en) * | 1996-03-25 | 2005-05-04 | Eli Lilly And Co., Indianapolis | TETRAHYDRO-BETA CARBOLINE COMPOUNDS |
US5886003A (en) * | 1996-03-25 | 1999-03-23 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of venomous bites and stings |
EA000769B1 (en) * | 1996-03-25 | 2000-04-24 | Эли Лилли Энд Компани | Method for treating migraine pain |
WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
AU777594B2 (en) * | 1999-05-24 | 2004-10-21 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
US20050065202A1 (en) * | 2003-05-09 | 2005-03-24 | Vidal Ramon Merce | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
KR20080044273A (en) | 2005-08-08 | 2008-05-20 | 아스텔라스세이야쿠 가부시키가이샤 | Acylguanidine derivative or salt thereof |
CN101384549B (en) * | 2006-02-20 | 2011-04-13 | 安斯泰来制药株式会社 | Pyrrole derivative or salt thereof |
BRPI0906244A2 (en) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Compound, pharmaceutical composition, method for treating a cognitive, psychotic, neurotransmitter mediated disorder or a neuronal disorder in an individual, use of a compound and kit |
EP2386546B1 (en) | 2008-11-21 | 2015-08-19 | RaQualia Pharma Inc | Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity |
TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
US20130137705A1 (en) * | 2009-09-23 | 2013-05-30 | Sarvajit Chakravarty | Pyrido[3,4-b]indoles and methods of use |
CN102724875B (en) | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | Pyrido[3,4-b]indoles and methods of use |
KR102401841B1 (en) | 2016-04-01 | 2022-05-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | estrogen receptor modulators |
WO2020176597A1 (en) * | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
AU2020326691A1 (en) | 2019-08-06 | 2022-03-03 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
CN116514824A (en) * | 2022-01-29 | 2023-08-01 | 上海科技大学 | Tri-ring compound, preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
DE3240514A1 (en) * | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | SS-CARBOLINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME |
US4520024A (en) * | 1983-02-11 | 1985-05-28 | Eli Lilly And Company | Method of selectively blocking peripheral vascular serotonergic receptors |
EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
-
1995
- 1995-03-10 AU AU21186/95A patent/AU679635B2/en not_active Ceased
- 1995-03-10 CZ CZ962649A patent/CZ264996A3/en unknown
- 1995-03-10 IL IL11295895A patent/IL112958A0/en unknown
- 1995-03-10 CN CN95193029A patent/CN1148340A/en active Pending
- 1995-03-10 EP EP95914014A patent/EP0749313A4/en not_active Withdrawn
- 1995-03-10 CA CA002185236A patent/CA2185236A1/en not_active Abandoned
- 1995-03-10 JP JP7523692A patent/JPH09510216A/en active Pending
- 1995-03-10 HU HU9602482A patent/HUT75522A/en unknown
- 1995-03-10 WO PCT/US1995/003099 patent/WO1995024200A1/en not_active Application Discontinuation
-
1996
- 1996-09-10 NO NO963785A patent/NO963785L/en unknown
- 1996-09-10 FI FI963571A patent/FI963571A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO963785L (en) | 1996-11-01 |
EP0749313A4 (en) | 2001-10-24 |
AU2118695A (en) | 1995-09-25 |
HU9602482D0 (en) | 1996-11-28 |
EP0749313A1 (en) | 1996-12-27 |
AU679635B2 (en) | 1997-07-03 |
FI963571A0 (en) | 1996-09-10 |
JPH09510216A (en) | 1997-10-14 |
CZ264996A3 (en) | 1998-01-14 |
WO1995024200A1 (en) | 1995-09-14 |
FI963571A (en) | 1996-11-08 |
CN1148340A (en) | 1997-04-23 |
HUT75522A (en) | 1997-05-28 |
CA2185236A1 (en) | 1995-09-14 |
IL112958A0 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963785D0 (en) | Process for the treatment of 5HT2B receptor-related conditions | |
NO976063D0 (en) | Procedure for the treatment of diabetes | |
NO961483D0 (en) | Process for the treatment of oily formation | |
NO991955L (en) | Process for the treatment of hydrocarbons | |
FI945441A (en) | New process for the preparation of 7beta-substituted-4-aza-5alpha-androstan-3-ones | |
NO981800L (en) | Process for the preparation of 1,1,1,3,3-pentafluoropentane | |
DE69520558D1 (en) | HALOGENING PROCESS | |
NO953443D0 (en) | Process for the treatment of solid waste | |
FI940769A (en) | Process for the preparation of 2-aminoazole derivatives | |
NO942906L (en) | Process for the oxidation of sodium sulfide | |
NO972402D0 (en) | Process for the preparation of carriers | |
NO961498D0 (en) | Process for the capture of sulfur compounds | |
FI973173A0 (en) | Process for the treatment of condensate | |
DE69507032T2 (en) | CHLORHYDRINE PROCESS | |
NO963187D0 (en) | Process for the synthesis of gamma-pyrones | |
NO953993D0 (en) | Process water treatment process | |
NO955082L (en) | Process for the preparation of glutardialdehyde | |
NO179244C (en) | Process for continuous preparation of dimethoxyethanol | |
NO973366D0 (en) | Procedure for the treatment of multiple sclerosis | |
NO982562D0 (en) | Composition for the treatment of pain | |
DE69527224D1 (en) | coating process | |
NO972682D0 (en) | New process for the preparation of sameridine | |
NO972129D0 (en) | Process for the preparation of 1-halo-3-trialkylsilanyl-benzene derivatives | |
FR2728566B1 (en) | PROCESS FOR THE PREPARATION OF PENTENE-NITRILES | |
NO962812D0 (en) | Procedure for the treatment of pneumonia |